Dr. Tella is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Mayo Clinic, 200 1st street SW
Rochester, MN 55901Phone+1 402-280-4180
Summary
- Dr. Sri Harsha Tella is an oncologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. He received his medical degree from Creighton University School of Medicine and has been in practice 6 years. He specializes in endocrine cancer and gastrointestinal cancer. He has more than 80 publications and over 2500 citings.
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2015 - 2017
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 2012 - 2015- Creighton University School of MedicineClass of 2011
Certifications & Licensure
ID State Medical License 2023 - 2026
MN State Medical License 2020 - 2023
SC State Medical License 2017 - 2021
DC State Medical License 2015 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Raisz-Drezner Awardee ASBMR, 2018
Publications & Presentations
PubMed
- 4 citationsProjected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States.Michael H Storandt, Sri Harsha Tella, Mikolaj A Wieczorek, David Hodge, Julia K Elrod
Cancers. 2024-02-06 - 1 citationsPhase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.Sri Harsha Tella, Nathan Foster, Shi Qian, Tran Nguyen, Mitesh J Borad
The Oncologist. 2023-10-03 - 8 citationsRole of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review.Charan Thej Reddy Vegivinti, Praneeth Reddy Keesari, Sindhusha Veeraballi, Catarina Maria Pina Martins Maia, Ansh Krishnachandra Mehta
Experimental Hematology & Oncology. 2023-07-08
Lectures
- Novel staging system using carbohydrate antigen (CA) 19-9 in extrahepatic cholangiocarcinoma (ECCC) and its implications on overall survival (OS).2019 ASCO Annual Meeting - 6/1/2019
- Disparities in the receipt of palliative care (PC) in metastatic renal cell carcinoma (mRCC).2019 ASCO Annual Meeting - 6/1/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
